NCT00299520View on ClinicalTrials.gov

Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)

PHASE3CompletedINTERVENTIONAL

Timeline

Start Date

June 30, 2005

Study Completion Date

July 31, 2006

Conditions

Complicated Skin and Skin Structure Infection

Interventions

DRUG

intravenous iclaprim or intravenous linezolid

Trial Locations (5)

21502

Judith Stone. M.D., Cumberland

43608

ID Clinical Research, Ltd., Toledo

46260

Infectious Disease of Indiana, Indianapolis

83702

VA Medical Center, Boise

91950

e-Study Site, National City

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Arpida AG

INDUSTRY

NCT00299520 - Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1) | Biotech Hunter | Biotech Hunter